Novo Nordisk CEO signals M&A opportunities to strengthen drug pipeline amid competition
Novo Nordisk CEO Mike Doustdar told CNBC on Tuesday that the pharmaceutical giant is considering M&A opportunities to strengthen its drug pipeline, as it faces growing competition in the weight-loss market. Doustdar stated the company is interested in filling gaps by acquiring firms that have produced or are about to introduce better drugs than Novo Nordisk can develop on its own.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
The Nikkei 225 Index fell 5.76% from its previous close, currently trading at 57,557.09.
-
2
ZEC (Zcash) is up 6.26% over the past 4 hours, currently trading at $1,330.13.
-
3
AUD/USD fell 0.89% from its previous close, currently trading at 0.6946.
-
4
The Shanghai Composite Index fell 1.06% from its previous close, currently trading at 3,650.85.
-
5
Taiwan Stock Exchange Weighted Index fell 6.11% from its previous close, currently trading at 39,032.95.
-
6
Brent crude was up 3.52% from its previous close, currently trading at $98.354.
-
7
South Korea's KOSPI index fell 5.48% from its previous close, currently standing at 5,088.79.
-
8
Trump's policies and institutional participation drove Ethereum's sharp rally in August 2026, with its market cap reaching approximately $294.8 billion in November
-
9
What is MTH (Monetha)? Project Positioning and Token Supply Analysis
-
10
Where to Buy MANA? A Comprehensive Guide to Decentraland Tokens and Mainstream Trading Channels
Markets Today
Recommended Reading




